STOCK TITAN

Astria Therapeutics Inc Stock Price, News & Analysis

ATXS Nasdaq

Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.

Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.

Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.

Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.

Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.

Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) has initiated the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215, aimed at treating hereditary angioedema (HAE). The trial will assess safety, tolerability, and quality of life for patients with HAE types I and II, with initial proof-of-concept results expected in mid-2024. Following promising Phase 1a results, Astria is optimistic about STAR-0215's potential as a long-acting preventative therapy. Additionally, preliminary results for six-month dosing are anticipated in Q4 2023, showcasing the company's commitment to addressing unmet needs in rare allergic and immunological diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ: ATXS) has granted stock options to purchase 1,800 shares of common stock on February 1, 2023. This is part of the 2022 Inducement Stock Incentive Plan, aimed at facilitating equity awards for new employees. The options have an exercise price of $13.36, equal to the closing stock price on the grant date, and will vest over four years. The first 25% will vest on the first anniversary of the employee's start date, with the remainder vesting monthly thereafter, contingent on continued employment. Astria is focused on therapies for rare allergic and immunological diseases, particularly with its lead program, STAR-0215.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary

Astria Therapeutics (NASDAQ: ATXS) has successfully closed its underwritten offering of 10,445,050 shares at $11.01 per share, raising approximately $115 million in gross proceeds. The offering included the full exercise of an underwriters' option for 1,362,397 additional shares. Jefferies and Evercore ISI served as joint book-running managers. The shares were offered under an effective shelf registration statement filed with the SEC. This funding supports the company's development of STAR-0215, aimed at treating hereditary angioedema and other rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
none
Rhea-AI Summary

Astria Therapeutics (ATXS) announced a public offering of 9,082,653 shares at $11.01 per share, aiming to raise approximately $100 million before expenses. Underwriters also hold a 30-day option to purchase an additional 1,362,397 shares. The offering is set to close around December 19, 2022, pending customary closing conditions. Jefferies and Evercore ISI are the joint book-running managers. The offering is conducted under a previously effective shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced successful preliminary results from the Phase 1a trial of STAR-0215, a potential long-acting treatment for hereditary angioedema (HAE). The drug demonstrated a favorable safety profile and sustained drug levels for up to three months, with an estimated half-life of 110 days. The company plans to initiate the ALPHA-STAR Phase 1b/2 trial in HAE patients in Q1 2023, aiming for less frequent dosing. Results from the trial indicate promising pharmacokinetics, enhancing the prospect of STAR-0215 as a viable treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the grant of stock options for 1,000 shares of its common stock as part of its 2022 Inducement Stock Incentive Plan. This grant, made on December 1, 2022, is aimed at new employees and complies with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.00, matching the stock's closing price on the grant date, and will vest over four years. Astria is focused on developing STAR-0215 for hereditary angioedema and aims to deliver therapies for rare allergic and immunological diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
none
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) reported Q3 2022 financial results, highlighting a net loss of $12 million and a loss per share of $0.87. The company is on track to release preliminary results from its Phase 1a clinical trial of STAR-0215, targeting hereditary angioedema, by the end of 2022. STAR-0215 shows promise with potential quarterly dosing based on preclinical data. Cash position stood at $116.6 million, sufficient to fund operations until mid-2024. R&D expenses increased to $7.7 million, while total expenses for the quarter were $12.4 million, reflecting ongoing development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.81%
Tags
-
Rhea-AI Summary

Astria Therapeutics (Nasdaq: ATXS) announced that CEO Jill C. Milne will present a corporate overview of the company and its lead program STAR-0215 at the Jefferies London Healthcare Conference on November 16 at 7:25 AM GMT. STAR-0215 is a monoclonal antibody being developed for the treatment of hereditary angioedema, targeting rare allergic and immunological diseases. Investors can access a live webcast of the presentation here, with an archived replay available for 30 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
conferences
-
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced the presentation of preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), at the 2022 ACAAI Annual Scientific Meeting in Louisville, Kentucky. The e-poster, titled "Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215," will be presented by Jou-Ku Chung on November 13, 2022 at 12:05 PM ET. STAR-0215 aims for long-lasting prevention of HAE attacks with dosing every three months. The ongoing Phase 1a clinical trial's preliminary results are expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.94%
Tags
conferences
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ: ATXS) announced the granting of stock options for 46,500 shares on November 1, 2022, under its 2022 Inducement Stock Incentive Plan. The options, available to new employees, have an exercise price of $10.71, matching the stock's closing price on the grant date. These options will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting monthly. The plan aligns with Nasdaq Listing Rule 5635(c)(4) for employee inducements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none

FAQ

What is the current stock price of Astria Therapeutics (ATXS)?

The current stock price of Astria Therapeutics (ATXS) is $6.85 as of August 15, 2025.

What is the market cap of Astria Therapeutics (ATXS)?

The market cap of Astria Therapeutics (ATXS) is approximately 387.7M.
Astria Therapeutics Inc

Nasdaq:ATXS

ATXS Rankings

ATXS Stock Data

387.70M
49.67M
0.49%
106.31%
5.47%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON